These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35820357)

  • 1. Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma.
    Ahn B; Yoon S; Kim D; Chun SM; Lee G; Kim HR; Jin Jang S; Sang Hwang H
    Lung Cancer; 2022 Aug; 170():176-184. PubMed ID: 35820357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
    Lee JS; Kim EK; Kim KA; Shim HS
    Cancer Res Treat; 2024 Jan; 56(1):104-114. PubMed ID: 37499696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Insights Into the International Association for the Study of Lung Cancer Grading System for Lung Adenocarcinoma.
    Tan KS; Reiner A; Emoto K; Eguchi T; Takahashi Y; Aly RG; Rekhtman N; Adusumilli PS; Travis WD
    Mod Pathol; 2024 Jul; 37(7):100520. PubMed ID: 38777035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.
    Jones GD; Brandt WS; Shen R; Sanchez-Vega F; Tan KS; Martin A; Zhou J; Berger M; Solit DB; Schultz N; Rizvi H; Liu Y; Adamski A; Chaft JE; Riely GJ; Rocco G; Bott MJ; Molena D; Ladanyi M; Travis WD; Rekhtman N; Park BJ; Adusumilli PS; Lyden D; Imielinski M; Mayo MW; Li BT; Jones DR
    JAMA Surg; 2021 Feb; 156(2):e205601. PubMed ID: 33355651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micropapillary and solid components as high-grade patterns in IASLC grading system of lung adenocarcinoma: Clinical implications and management.
    Mikubo M; Tamagawa S; Kondo Y; Hayashi S; Sonoda D; Naito M; Shiomi K; Ichinoe M; Satoh Y
    Lung Cancer; 2024 Jan; 187():107445. PubMed ID: 38157805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and Genotypic Features of Lung Adenocarcinoma Characterized by the International Association for the Study of Lung Cancer Grading System.
    Fujikawa R; Muraoka Y; Kashima J; Yoshida Y; Ito K; Watanabe H; Kusumoto M; Watanabe SI; Yatabe Y
    J Thorac Oncol; 2022 May; 17(5):700-707. PubMed ID: 35227909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.
    Akhave N; Zhang J; Bayley E; Frank M; Chiou SH; Behrens C; Chen R; Hu X; Parra ER; Lee WC; Swisher S; Solis L; Weissferdt A; Moran C; Kalhor N; Zhang J; Scheet P; Vaporciyan AA; Sepesi B; Gibbons DL; Heymach JV; Lee JJ; Wistuba II; Andrew Futreal P; Zhang J; Fujimoto J; Reuben A
    Lung Cancer; 2022 Oct; 172():19-28. PubMed ID: 35973335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection.
    Jiang MQ; Qian LQ; Shen YJ; Fu YY; Feng W; Ding ZP; Han YC; Fu XL
    Neoplasia; 2024 Apr; 50():100979. PubMed ID: 38387107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
    Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
    Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
    Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
    PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
    Caso R; Sanchez-Vega F; Tan KS; Mastrogiacomo B; Zhou J; Jones GD; Nguyen B; Schultz N; Connolly JG; Brandt WS; Bott MJ; Rocco G; Molena D; Isbell JM; Liu Y; Mayo MW; Adusumilli PS; Travis WD; Jones DR
    J Thorac Oncol; 2020 Dec; 15(12):1844-1856. PubMed ID: 32791233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
    Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
    Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparate genomic characteristics of patients with early-stage lung adenocarcinoma manifesting as radiological subsolid or solid lesions.
    Li H; Sun Z; Li Y; Qi Q; Huang H; Wang X; Zhou J; Liu K; Yin P; Wang Z; Li X; Yang F
    Lung Cancer; 2022 Apr; 166():178-188. PubMed ID: 35303645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The IASLC Proposed Grading System Accurately Predicts Prognosis and Mediastinal Nodal Metastasis in Patients With Clinical Stage I Lung Adenocarcinoma.
    Xu L; Su H; Hou L; Wang F; Xie H; She Y; Gao J; Zhao S; Dai C; Xie D; Zhu Y; Wu C; Zhao D; Chen C;
    Am J Surg Pathol; 2022 Dec; 46(12):1633-1641. PubMed ID: 36224092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade tumor classified by new system is a prognostic predictor in resected lung adenocarcinoma.
    Yoshida C; Yokomise H; Ibuki E; Go T; Haba R; Kadota K
    Gen Thorac Cardiovasc Surg; 2022 May; 70(5):455-462. PubMed ID: 35050467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.
    Wang H; Wang X; Xu L; Cao H; Zhang J
    Cancer Med; 2021 Dec; 10(24):9058-9077. PubMed ID: 34734491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
    Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
    Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.